
Kevin Kai Hill
Examiner (ID: 9255, Phone: (571)272-8036 , Office: P/1633 )
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1631, 1638, 1633 |
| Total Applications | 1127 |
| Issued Applications | 332 |
| Pending Applications | 128 |
| Abandoned Applications | 680 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17168901
[patent_doc_number] => 20210322571
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => AAV VECTOR FOR TREATMENT OF FRIEDREICH'S ATAXIA
[patent_app_type] => utility
[patent_app_number] => 17/365845
[patent_app_country] => US
[patent_app_date] => 2021-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12354
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365845
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/365845 | AAV VECTOR FOR TREATMENT OF FRIEDREICH'S ATAXIA | Jun 30, 2021 | Pending |
Array
(
[id] => 18510120
[patent_doc_number] => 20230226221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => USE OF RECOMBINANT HUMAN ACID SPHINGOMYELINASE TO IMPROVE SKELETAL MYOFIBER REPAIR
[patent_app_type] => utility
[patent_app_number] => 18/008422
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12803
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18008422
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/008422 | USE OF RECOMBINANT HUMAN ACID SPHINGOMYELINASE TO IMPROVE SKELETAL MYOFIBER REPAIR | Jun 28, 2021 | Pending |
Array
(
[id] => 17156123
[patent_doc_number] => 20210317174
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/356214
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29995
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356214
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/356214 | COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES | Jun 22, 2021 | Abandoned |
Array
(
[id] => 18565790
[patent_doc_number] => 20230256117
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => GENE THERAPY EXPRESSION SYSTEM ALLOWING AN ADEQUATE EXPRESSION IN THE MUSCLES AND IN THE HEART OF SGCG
[patent_app_type] => utility
[patent_app_number] => 18/001648
[patent_app_country] => US
[patent_app_date] => 2021-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13854
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001648
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/001648 | GENE THERAPY EXPRESSION SYSTEM ALLOWING AN ADEQUATE EXPRESSION IN THE MUSCLES AND IN THE HEART OF SGCG | Jun 17, 2021 | Pending |
Array
(
[id] => 18582929
[patent_doc_number] => 20230265186
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => CHIMERIC ANTIGEN RECEPTOR CELL
[patent_app_type] => utility
[patent_app_number] => 18/009320
[patent_app_country] => US
[patent_app_date] => 2021-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21341
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009320
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/009320 | CHIMERIC ANTIGEN RECEPTOR CELL | Jun 8, 2021 | Pending |
Array
(
[id] => 19417331
[patent_doc_number] => 20240293454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => TCR-T CELL FOR KILLING TUMORS, AND PREPARATION METHOD THEREFOR AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/016293
[patent_app_country] => US
[patent_app_date] => 2021-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6705
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016293
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/016293 | TCR-T CELL FOR KILLING TUMORS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jun 1, 2021 | Pending |
Array
(
[id] => 17110083
[patent_doc_number] => 20210290680
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => METHODS AND COMPOSITIONS FOR MODULATING CELLULAR AGING
[patent_app_type] => utility
[patent_app_number] => 17/332886
[patent_app_country] => US
[patent_app_date] => 2021-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16688
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332886
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/332886 | METHODS AND COMPOSITIONS FOR MODULATING CELLULAR AGING | May 26, 2021 | Abandoned |
Array
(
[id] => 18485273
[patent_doc_number] => 20230212606
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS
[patent_app_type] => utility
[patent_app_number] => 17/923636
[patent_app_country] => US
[patent_app_date] => 2021-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 85502
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -96
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923636
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/923636 | COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS | May 11, 2021 | Pending |
Array
(
[id] => 17292191
[patent_doc_number] => 20210388030
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => COMPOSITIONS AND METHODS FOR INTRAVITREAL DELIVERY OF POLYNUCLEOTIDES TO RETINAL CONES
[patent_app_type] => utility
[patent_app_number] => 17/308785
[patent_app_country] => US
[patent_app_date] => 2021-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26644
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308785
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/308785 | COMPOSITIONS AND METHODS FOR INTRAVITREAL DELIVERY OF POLYNUCLEOTIDES TO RETINAL CONES | May 4, 2021 | Abandoned |
Array
(
[id] => 18511674
[patent_doc_number] => 20230227856
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => SELECTION BY ESSENTIAL-GENE KNOCK-IN
[patent_app_type] => utility
[patent_app_number] => 17/923358
[patent_app_country] => US
[patent_app_date] => 2021-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 111475
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -212
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923358
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/923358 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | May 3, 2021 | Pending |
Array
(
[id] => 18420473
[patent_doc_number] => 20230174935
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => REPEAT DOSING OF HYPOIMMUNOGENIC CELLS
[patent_app_type] => utility
[patent_app_number] => 17/997103
[patent_app_country] => US
[patent_app_date] => 2021-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55602
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -250
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997103
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/997103 | REPEAT DOSING OF HYPOIMMUNOGENIC CELLS | Apr 26, 2021 | Pending |
Array
(
[id] => 17050768
[patent_doc_number] => 20210260202
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => Methods and Compositions Related to Annexin 1-Binding Compounds
[patent_app_type] => utility
[patent_app_number] => 17/240714
[patent_app_country] => US
[patent_app_date] => 2021-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33098
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240714
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/240714 | Methods and Compositions Related to Annexin 1-Binding Compounds | Apr 25, 2021 | Abandoned |
Array
(
[id] => 17255766
[patent_doc_number] => 20210368751
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => HUMANIZED RODENTS THAT EXPRESS HEAVY CHAIN CONTAINING VL DOMAINS
[patent_app_type] => utility
[patent_app_number] => 17/224524
[patent_app_country] => US
[patent_app_date] => 2021-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53415
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17224524
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/224524 | HUMANIZED RODENTS THAT EXPRESS HEAVY CHAIN CONTAINING VL DOMAINS | Apr 6, 2021 | Abandoned |
Array
(
[id] => 17242035
[patent_doc_number] => 20210361778
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR IDS GENE TRANSFER AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/222659
[patent_app_country] => US
[patent_app_date] => 2021-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37035
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222659
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/222659 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR IDS GENE TRANSFER AND METHODS OF USE THEREOF | Apr 4, 2021 | Abandoned |
Array
(
[id] => 17067590
[patent_doc_number] => 20210269805
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => Transcription Factor Trapping by RNA in Gene Regulatory Elements
[patent_app_type] => utility
[patent_app_number] => 17/217612
[patent_app_country] => US
[patent_app_date] => 2021-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53489
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17217612
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/217612 | Transcription Factor Trapping by RNA in Gene Regulatory Elements | Mar 29, 2021 | Pending |
Array
(
[id] => 19281893
[patent_doc_number] => 20240218367
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => Targeted Destruction of Viral RNA by CRISPR-Cas13
[patent_app_type] => utility
[patent_app_number] => 17/907121
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62431
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907121
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/907121 | Targeted Destruction of Viral RNA by CRISPR-Cas13 | Mar 25, 2021 | Abandoned |
Array
(
[id] => 18322937
[patent_doc_number] => 20230121065
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => METHOD OF DELIVERING NUCLEIC ACID TO IMMUNE CELLS USING RBCEV
[patent_app_type] => utility
[patent_app_number] => 17/914194
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23304
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914194
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/914194 | METHOD OF DELIVERING NUCLEIC ACID TO IMMUNE CELLS USING RBCEV | Mar 24, 2021 | Abandoned |
Array
(
[id] => 18842642
[patent_doc_number] => 20230405046
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
[patent_app_type] => utility
[patent_app_number] => 17/906448
[patent_app_country] => US
[patent_app_date] => 2021-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45280
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906448
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/906448 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES | Mar 14, 2021 | Pending |
Array
(
[id] => 17168908
[patent_doc_number] => 20210322578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/200725
[patent_app_country] => US
[patent_app_date] => 2021-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17200725
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/200725 | ONCOLYTIC VACCINIA VIRUS CANCER THERAPY | Mar 11, 2021 | Abandoned |
Array
(
[id] => 18308175
[patent_doc_number] => 20230112075
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => COMPOSITIONS AND METHODS FOR MODIFYING A TARGET NUCLEIC ACID
[patent_app_type] => utility
[patent_app_number] => 17/911387
[patent_app_country] => US
[patent_app_date] => 2021-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15007
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911387
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/911387 | COMPOSITIONS AND METHODS FOR MODIFYING A TARGET NUCLEIC ACID | Mar 11, 2021 | Pending |